Biology subjects

Palepu, A.

Publications and source records attributed to Palepu, A..

4 recordsLinked to original sources

bioRxiv2025

AI-assisted Drug Re-purposing for Human Liver Fibrosis

Liver fibrosis is a severe disease with few treatment options due to the poor quality of the available animal and in vitro models. To address this, we investigated whether a hypothesis generating multi-agent AI system (AI co-scientist) could assist in re-purposing drugs for treatment of liver fibrosis and direct their experimental characterization. A multi-parameter image analysis workflow, which enabled anti-fibrotic efficacy and drug toxicity to be serially assessed in multi-lineage human hepatic organoids grown in microwells (i.e., microHOs), was used to assess the effects of 14 drugs. Remarkably, two of the three AI co-scientist-recommended drugs that targeted epigenomic modifiers exhibited significant anti-fibrotic activity. Analysis of the anti-fibrotic effects of five drugs indicated that two inhibited TGF{beta}-induced intracellular signaling and three drugs altered TGF{beta}-induced mesenchymal cell differentiation. Since all five of the anti-fibrotic drugs reduced TGF{beta}-induced chromatin structural changes, epigenomic changes play an important role in the pathogenesis of liver fibrosis. One AI co-scientist recommended drug is an FDA-approved anti-cancer treatment (Vorinostat) that reduced TGF{beta}-induced chromatin structural changes by 91% and promoted liver parenchymal cell regeneration in microHOs. Hence, the use of AI co-scientist and this microHO platform identified a potential new generation of liver fibrosis treatments that also promote liver regeneration.

bioinformatics↗

bioRxiv2025

AI mirrors experimental science to uncover a novel mechanism of gene transfer crucial to bacterial evolution

AI models have been proposed for hypothesis generation, but testing their ability to drive high-impact research is challenging, since an AI-generated hypothesis can take decades to validate. Here, we challenge the ability of a recently developed LLM-based platform, AI co-scientist, to generate high-level hypotheses by posing a question that took years to resolve experimentally but remained unpublished: How could capsid-forming phage-inducible chromosomal islands (cf-PICIs) spread across bacterial species? Remarkably, AI co-scientists top-ranked hypothesis matched our experimentally confirmed mechanism: cf-PICIs hijack diverse phage tails to expand their host range. We critically assess its five highest-ranked hypotheses, showing that some opened new research avenues in our laboratories. We benchmark its performance against other LLMs and outline best practices for integrating AI into scientific discovery. Our findings suggest that AI can act not just as a tool but as a creative engine, accelerating discovery and reshaping how we generate and test scientific hypotheses.

microbiology↗

bioRxiv2023

Genetic Discovery Enabled by A Large Language Model

Artificial intelligence (AI) has been used in many areas of medicine, and recently large language models (LLMs) have shown potential utility for clinical applications. However, since we do not know if the use of LLMs can accelerate the pace of genetic discovery, we used data generated from mouse genetic models to investigate this possibility. We examined whether a recently developed specialized LLM (Med-PaLM 2) could analyze sets of candidate genes generated from analysis of murine models of biomedical traits. In response to free-text input, Med-PaLM 2 correctly identified the murine genes that contained experimentally verified causative genetic factors for six biomedical traits, which included susceptibility to diabetes and cataracts. Med-PaLM 2 was also able to analyze a list of genes with high impact alleles, which were identified by comparative analysis of murine genomic sequence data, and it identified a causative murine genetic factor for spontaneous hearing loss. Based upon this Med-PaLM 2 finding, a novel bigenic model for susceptibility to spontaneous hearing loss was developed. These results demonstrate Med-PaLM 2 can analyze gene-phenotype relationships and generate novel hypotheses, which can facilitate genetic discovery.

genetics↗

bioRxiv2019

Evaluating Invasive EEG Implantations in Medically Refractory Epilepsy with Functional Scalp EEG Recordings and Structural Imaging Data

Seizures in patients with medically refractory epilepsy (MRE) epilepsy cannot be controlled with drugs. For focal MRE, seizures originate in the epileptogenic zone (EZ), which is the minimum amount of cortex that must be treated to be seizure free. Localizing the EZ is often a laborious process wherein clinicians first inspect scalp EEG recordings during several seizure events, and then formulate an implantation plan for subsequent invasive monitoring. The goal of implantation is to place electrodes into the brain region covering the EZ. Then, during invasive monitoring, clinicians visually inspect intracranial EEG recordings to more precisely localize the EZ. The EZ is then surgically removed. Unfortunately surgical success rates average at 50%. Such grim outcomes call for analytical assistance in creating more accurate implantation plans from scalp EEG. In this paper, we introduce a method that combines imaging data (CT and MRI scans) with scalp EEG to derive an implantation distribution. Specifically, scalp EEG data recorded over a seizure event is converted into a time-gamma frequency map, which is then processed to derive a spectrally annotated implantation distribution (SAID). The SAID represents a distribution of gamma power in each of the eight cortical lobe/hemisphere partitions. We applied this method to 4 MRE patients who underwent treatment, and found that the SAID distribution overlapped more with clinical implantations in success cases than in failed cases. These preliminary findings suggest that the SAID may help in improving EZ localization accuracy and surgical outcomes.

neuroscience↗